Catalyst

Slingshot members are tracking this event:

Tesaro (TSRO) Presents Phase 3 ENGOT-OV16/NOVA Data Evaluating Niraparib in Ovarian Cancer Regardless of BRCA Status

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
TSRO

100%
Slingshot Insights Explained
Catalyst Date
Occurred on:
Oct 10, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Niraparib, Phase 3, Engot-ov16/nova, Ovarian Cancer, European Society For Medical Oncology 2016, Annual Meeting